Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

15.32USD
21 May 2018
Change (% chg)

-- (--)
Prev Close
$15.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
880,987
52-wk High
$18.75
52-wk Low
$7.15

Latest Key Developments (Source: Significant Developments)

Array Biopharma Says Entered Into Controlled Equity Offerings Sales Agreement With Cantor Fitzgerald
Wednesday, 9 May 2018 08:37am EDT 

May 9 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA INC SAYS ENTERED INTO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING.ARRAY BIOPHARMA INC SAYS MAY OFFER AND SELL UP TO $125.0 MILLION OF COMMON STOCK OF THROUGH CANTOR FITZGERALD & CO.  Full Article

Array Biopharma Q2 Loss Per Share $0.17
Tuesday, 6 Feb 2018 08:05am EST 

Feb 6 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF FISCAL 2018.Q2 LOSS PER SHARE $0.17.Q2 REVENUE $42.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.23, REVENUE VIEW $26.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Array Biopharma Contributes Rights And Assets Related To Arry-797 Drug Program To Yarra Therapeutics
Friday, 22 Dec 2017 06:12am EST 

Dec 22 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA SAYS ON DEC 21, CO CONTRIBUTED CERTAIN RIGHTS AND ASSETS RELATED TO ARRY-797 DRUG PROGRAM TO YARRA THERAPEUTICS - SEC FILING.ARRAY BIOPHARMA SAYS FORMED YARRA TO FURTHER DEVELOP, COMMERCIALIZE THERAPEUTICS TARGETED TOWARDS RARE DISEASES, INCLUDING ARRY-797 DRUG PROGRAM.ARRAY BIOPHARMA - YARRA WILL BE LED BY BRYAN STUART, WHO WILL SERVE AS YARRA'S PRESIDENT AND CHIEF EXECUTIVE OFFICER.  Full Article

Array BioPharma Announces Strategic Collaboration With Pfizer
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA ANNOUNCES STRATEGIC COLLABORATION WITH PFIZER.ARRAY BIOPHARMA SAYS UNDER COLLABORATION AGREEMENT, TRIAL WILL BE SPONSORED AND FUNDED BY PFIZER, WITH ARRAY PROVIDING BINIMETINIB SUPPLY.ARRAY BIOPHARMA - PHASE 1B CLINICAL STUDY IS EXPECTED TO BEGIN BY Q3 2018.ARRAY BIOPHARMA - ENTERED INTO CLINICAL TRIAL AGREEMENT WITH PFIZER TO INVESTIGATE SAFETY, EFFICACY OF SEVERAL NOVEL ANTI-CANCER COMBINATIONS.  Full Article

Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes
Monday, 4 Dec 2017 04:42pm EST 

Dec 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION.ARRAY BIOPHARMA SAYS ‍2024 NOTES WILL MATURE ON DEC 1, 2024​ - SEC FILING.ARRAY - ALSO ISSUED AGGREGATE OF ABOUT 7.96 MILLION SHARES OF CO'S COMMON STOCK IN EXCHANGE OF $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020​.ARRAY BIOPHARMA - ‍2024 NOTES TO BEAR INTEREST AT 2.625% PAYABLE SEMIANNUALLY IN ARREARS ON JUNE 1 & DEC 1 OF EACH YEAR, BEGINNING JUNE 1, 2018​.  Full Article

Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Array Biopharma Inc :Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting.Array Biopharma Inc - ‍plans to expand ongoing phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer​.  Full Article

ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Array Biopharma Inc :ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018.Q1 LOSS PER SHARE $0.22.Q1 REVENUE $29.7 MILLION VERSUS I/B/E/S VIEW $33.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.‍INCREASE IN QTRLY NET LOSS WAS PRIMARILY DUE TO A DECREASE IN REIMBURSEMENT REVENUE FROM NOVARTIS​.‍INCREASE IN QTRLY NET LOSS WAS ALSO PRIMARILY DUE TO A DECREASE IN NON-RECURRING COSTS FOR COMMERCIAL DRUG SUPPLY FROM NOVARTIS​.  Full Article

Array Biopharma announces proposed public offering of common stock
Wednesday, 13 Sep 2017 04:02pm EDT 

Sept 14 (Reuters) - Array Biopharma Inc :Array Biopharma announces proposed public offering of common stock.Array Biopharma Inc - ‍commenced an underwritten public offering of $175 million of shares of its common stock.​.  Full Article

Point72 Asset Management reports 5.4 percent passive stake in Array Biopharma Inc
Tuesday, 12 Sep 2017 05:34pm EDT 

Sept 12 (Reuters) - Array Biopharma Inc :Point72 Asset Management L.P reports 5.4 percent passive stake in Array Biopharma Inc as of September 11, 2017 - SEC filing‍​.  Full Article

Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma
Tuesday, 12 Sep 2017 09:10am EDT 

Sept 12 (Reuters) - Array Biopharma Inc :Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma.Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues​.Array Biopharma Inc - ‍FDA set a target action date under pdufa of june 30, 2018 for both applications​.Array Biopharma Inc - ‍fda informed array that they are not currently planning to hold an advisory committee meeting to discuss NDAs​.  Full Article

BRIEF-Array Biopharma Says Entered Into Controlled Equity Offerings Sales Agreement With Cantor Fitzgerald

* ARRAY BIOPHARMA INC SAYS ENTERED INTO CONTROLLED EQUITY OFFERINGSM SALES AGREEMENT WITH CANTOR FITZGERALD & CO - SEC FILING